WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study
Authors:
- Yoshiko HashiiYHYoshiko Hashii
- Yoshihiro OkaYOYoshihiro Oka
- Naoki SakataNSNaoki Sakata
- Yusuke OjiYusuke Oji
- Naoki HosenNHNaoki Hosen
- Satoshi HattoriSHSatoshi Hattori
- Hiroko NakajimaHNHiroko Nakajima
- Jun NakataJNJun Nakata
- Fumihiro FujikiFFFumihiro Fujiki
- Soyoko MorimotoSMSoyoko Morimoto
- Shigeo FujiSFShigeo Fuji
Open Access
- 16 June 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (16) , 5531-5542
Abstract
This phase II clinical study evaluated the efficacy and safety of post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) maintenance cancer immunotherapy using two WT1 peptide vaccines-MCI-for pediatric refractory acute leukemias. Each of 17 patients (median age, 8.3 years; age range, 2-18 years) was intradermally injected with either of the vaccines. The 3-year overall survival (OS) rate-the primary endpoint-was 70.6% [95% confidence interval (CI), 43.1-86.6%]; this rate was higher than 30%, a historical control benchmark, and was attributable to the fact that 12 clinical responders-who sustained complete remission at year 1 after the initiation of vaccination-had a high 3-year OS rate of 91.7% (95% CI, 53.9-98.7%). WT1-specific cytotoxic T cell (CTL) frequency in peripheral blood (PB) from all of 12 clinical responders increased significantly after vaccination, reaching the maximum by week 12 of vaccination (before, 0.25±0.08%; after, 1.07±0.24%; P <.001), while WT1-specific CTL frequency in PB from clinical nonresponders remained unchanged after vaccination (before, 0.12±0.2%; after, 0.20±0.25%; P=.424). The estimated 3-year OS rate was significantly higher for 11 immune responders (who showed a ³1.455-fold increase from the baseline value: 90.9%) than for 5 immune nonresponders (40.0%; P=.027). Elevated WT1-specific CTL frequency in PB before vaccination predicted the subsequent favorable prognosis of all patients. No patients discontinued treatment due to MCI. Adverse events including graft-versus-host disease were manageable. MCI was suggested to be very effective and safe for pediatric patients with refractory acute leukemias, indicating its potential to improve their survival through relapse prevention. UMIN000005319Keywords
This publication has 47 references indexed in Scilit:
- Combination of disease burden before allogeneic transplantation and early post-transplant minimal residual disease predicts survival in patients with acute myeloid leukemiaAnnals of Hematology, 2025
- A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant gliomaCancer Immunology, Immunotherapy, 2018
- Graft versus Leukemia Reactivity after Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2011
- Prevention of GVHD without losing GVL effect: windows of opportunityImmunologic Research, 2010
- WT1 peptide immunotherapy for cancer in children and young adultsPediatric Blood & Cancer, 2010
- Potential of dendritic cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide‐ and keyhole limpet hemocyanin‐pulsed, donor‐derived dendritic cell vaccine for acute myeloid leukemiaAmerican Journal of Hematology, 2007
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcomeTransplantation and Cellular Therapy, 2003
- Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residuesCancer Immunology, Immunotherapy, 2002
- Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene ( WT1 ) productImmunogenetics, 2000